Table 1.
Subject Characteristics.
| Statin Non-Users | Statin Users | ||||
|---|---|---|---|---|---|
| APOE ε4- (n = 201) |
APOE ε4+ (n = 81) |
APOE ε4- (n = 39) |
APOE 4+ (n = 17) |
p-value | |
| Gender (F/M) | 95/106 | 43/38 | 17/22 | 7/10 | 0.5950 |
| Mem imp (MI/intact) | 48/153 | 33/48 | 3/36 | 3/14 | 0.0007 |
| FPG (mmol/L) | 5.39±0.82 | 5.47±0.83 | 5.67±0.69 | 5.88±0.46 | 0.0058 |
| FPI (pmol/L) | 84.0±70/8 | 81.3±60.4 | 129.9±88.9 | 80.6±44.4 | 0.0018 |
| Age (yrs) | 73.1±7.1 | 72.5±7.0 | 74.9±5.8 | 73.1±7.5 | 0.3699 |
| BMI (kg/m2) | 26.3±4.7 | 25.9±4.4 | 28.7±4.9 | 28.2±4.2 | 0.0071 |
| DRS | 136.4±9.1 | 130.3±15.9 | 138.5±4.3 | 137.6±5.1 | 0.0001 |
| Education (yrs) | 15.0±2.7 | 14.7±2.5 | 14.7± 2.6 | 14.8±2.5 | 0.7626 |
Gender (F/M = female/male) and Mem imp (MI/intact = memory impaired/cognitively intact individuals) are expressed as sample sizes; p-values were derived from χ2 tests. FPG (fasting plasma glucose; sig. by statin use, p < .01), FPI (fasting plasma insulin; sig. by APOE and Statin use and APOE × Statin use, p < .05), Age, BMI (body mass index; sig. by statin use, p < .01), DRS (Mattis Dementia Rating Scale; sig. by APOE, p < .01 and Statin use, p < .05), and Education are expressed as mean±standard deviation; p-values were derived from two-way ANOVAs (statin use by APOE genotype) without covariates. The DRS is a measure of overall cognitive function; test ceiling = 144, suggested dementia cutoff = 123.